64 Sidney Street, Cambridge, MA, 02139
- Biological research has been fascinating to me since my undergraduate years.
- During my 5-year Ph.D. program in the Department of Pharmacology and Cancer Biology at Duke University,
- I studied metabolism of lymphocytes under different conditions including resting, activation and pathological stage, such as acute and chronic leukemia.
- The goal of my study was to identify metabolic inhibitors specifically targeting disease stage lymphocytes.
- My training included but not limited to developing metabolic analysis, cell apoptosis assays and generating various animal models.
- I acquired skills to initiate and develop scientific projects, use statistical software R to analyze data, present research work, write manuscripts and grant proposals.
- I also participated in Duke Scholars in Molecular Medicine program that let me gain insights of clinical practices and translational research. After graduating from Duke University,
- I acquired a postdoctoral fellow position in Dr. Jeffrey Engelman's lab at Massachusetts General Hospital in March, 2015 and initiated two projects studying immunological and metabolic approaches to treat Kras mutant non-small cell lung cancer (NSCLC). In 2016,
- I transitioned to Novartis to continue my postdoc research when my mentor Dr. Engelman accepted a job offer from Novartis. At Novartis, I have two research projects.
- The first project focuses on understanding immuno-microenvironment of HPV-related papilloma including profiling activation and exhaustion markers on T lymphocytes and designing assays to test T cell functions and responses to immuno-checkpoint inhibitors.
- The second project aims at developing an ex vivo autologous tumor and lymphocytes co-culture system to test efficacy of immuno-modulating reagents.
- These projects are co-mentored by Dr. Jeffrey Engelman and Dr. Catherine Sabatos-Peyton.